title: Neutrophil-platelet adhesion: relative roles of platelet P-selectin and neutrophil beta2 (DC18) integrins.
abstract: Neutrophils and platelets interact both physically and metabolically during inflammation and thrombosis, but the mechanisms responsible for their adhesion remain incompletely understood. Neutrophil-platelet adhesion was measured after specific stimulation of neutrophils, platelets, or both and quantified by flow cytometry. Specific stimulation of either the neutrophil or the platelet led to a marked increase in the percentage of neutrophils that bound platelets, although platelet stimulation led to a large increase and neutrophil stimulation to only a small increase in the number of platelets per neutrophil. Stimulation of both cells further increased the number of neutrophil-platelet adhesive events and led to large numbers of platelets binding to each neutrophil. Confirming previous observations, blocking antibodies to platelet P-selectin (CD62P) partially inhibited adhesion. However, blockade of the neutrophil beta2 integrin CD11b/CD18 also inhibited the percentage of neutrophils that bound platelets. Combining P-selectin and CD11b/18 blockade further inhibited the stimulated increase in the percentage of neutrophils binding platelets and the increased number of platelets per neutrophil. Both cell adhesion molecules were active even when only a single cell type was primarily activated, supporting physiologically important transcellular activation. These data suggest that: (1) neutrophil-platelet adhesion can be initiated by specific activation of either the neutrophil or the platelet and that specific activation of either cell type leads to distinct patterns of adhesion, and (2) neutrophil-platelet adhesion uses both platelet P-selectin and the neutrophil beta2 integrin CD11b/CD18 when the cells are primarily or secondarily activated.
authors.affiliation: Department of Medicine, National Jewish Center for Immunology and Respiratory Medicine, University of Colorado Health Sciences Center, Denver 80206, USA. brownk@njc.org
authors.forename: K K
authors.initials: KK
authors.lastname: Brown
authors.forename: P M
authors.initials: PM
authors.lastname: Henson
authors.forename: J
authors.initials: J
authors.lastname: Maclouf
authors.forename: M
authors.initials: M
authors.lastname: Moyle
authors.forename: J A
authors.initials: JA
authors.lastname: Ely
authors.forename: G S
authors.initials: GS
authors.lastname: Worthen
mesh_terms: D000906:Antibodies / Q000494:pharmacology; D001792:Blood Platelets / Q000502:physiology* / Q000648:ultrastructure; D018821:CD18 Antigens / Q000276:immunology / Q000502:physiology*; D002448:Cell Adhesion; D006801:Humans; D007700:Kinetics; D008854:Microscopy, Electron; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D009504:Neutrophils / Q000502:physiology* / Q000648:ultrastructure; D009842:Oligopeptides / Q000494:pharmacology; D019007:P-Selectin / Q000276:immunology / Q000502:physiology*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D013917:Thrombin / Q000494:pharmacology
chemical_list: D000906:Antibodies; D018821:CD18 Antigens; D009842:Oligopeptides; D019007:P-Selectin; D010975:Platelet Aggregation Inhibitors; D009240:N-Formylmethionine Leucyl-Phenylalanine; C046617:arginyl-glycyl-aspartyl-serine; D013917:Thrombin